438 related articles for article (PubMed ID: 32047951)
21. Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Goeree R; Burke N; Jobin M; Brown JP; Lawrence D; Stollenwerk B; Willems D; Johnson B
Arch Osteoporos; 2022 Apr; 17(1):71. PubMed ID: 35471711
[TBL] [Abstract][Full Text] [Related]
22. In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate alone.
Hirsch C
Ann Intern Med; 2018 Jan; 168(2):JC3. PubMed ID: 29335715
[No Abstract] [Full Text] [Related]
23. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
[TBL] [Abstract][Full Text] [Related]
24. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
Hagino H; Tanaka K; Silverman S; McClung M; Gandra SR; Charokopou M; Adachi K; Johnson B; Stollenwerk B
Osteoporos Int; 2021 Oct; 32(10):2011-2021. PubMed ID: 33772328
[TBL] [Abstract][Full Text] [Related]
26. [Romosozumab : a new treatment for severe osteoporosis].
Uebelhart B; Ferrari S
Rev Med Suisse; 2021 Apr; 17(735):784-787. PubMed ID: 33881241
[TBL] [Abstract][Full Text] [Related]
27. [Sequential treatment of osteoporosis with anti-sclerostin.].
Inoue D
Clin Calcium; 2019; 29(3):363-369. PubMed ID: 30814383
[TBL] [Abstract][Full Text] [Related]
28. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
[TBL] [Abstract][Full Text] [Related]
29. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
[TBL] [Abstract][Full Text] [Related]
30. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.
Lim SY
Womens Health (Lond); 2022; 18():17455057221125577. PubMed ID: 36154750
[TBL] [Abstract][Full Text] [Related]
31. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
33. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
34. Romosozumab for the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
[TBL] [Abstract][Full Text] [Related]
35. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Safety and Sclerostin Inhibition.
Langdahl BL; Hofbauer LC; Forfar JC
J Clin Endocrinol Metab; 2021 Jun; 106(7):1845-1853. PubMed ID: 33755157
[TBL] [Abstract][Full Text] [Related]
37. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis.
Singh S; Dutta S; Khasbage S; Kumar T; Sachin J; Sharma J; Varthya SB
Osteoporos Int; 2022 Jan; 33(1):1-12. PubMed ID: 34432115
[TBL] [Abstract][Full Text] [Related]
38. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
McClung MR; Betah D; Deignan C; Shi Y; Timoshanko J; Cosman F
Endocr Pract; 2023 Sep; 29(9):716-722. PubMed ID: 37406858
[TBL] [Abstract][Full Text] [Related]
39. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
Poole KE; Treece GM; Pearson RA; Gee AH; Bolognese MA; Brown JP; Goemaere S; Grauer A; Hanley DA; Mautalen C; Recknor C; Yang YC; Rojeski M; Libanati C; Whitmarsh T
J Bone Miner Res; 2022 Feb; 37(2):256-264. PubMed ID: 34738660
[TBL] [Abstract][Full Text] [Related]
40. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Turk JR; Deaton AM; Yin J; Stolina M; Felx M; Boyd G; Bienvenu JG; Varela A; Guillot M; Holdsworth G; Wolfreys A; Dwyer D; Kumar SV; de Koning EM; Qu Y; Engwall M; Locher K; Ward LD; Glaus C; He YD; Boyce RW
Regul Toxicol Pharmacol; 2020 Aug; 115():104697. PubMed ID: 32590049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
